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Abstract
Background: There is currently no drug therapy to prevent arthrofibrosis following knee surgery. We aimed to
determine if the anti-ischemic and anti-inflammatory drug adenosine, lidocaine and Mg2+ (ALM), reduces surgery-
related arthrofibrosis in a rat model of knee implant surgery.
Methods: Male Sprague-Dawley rats (n = 24) were randomly divided into ALM or saline groups. The right knee of
each animal was implanted with custom titanium (femur) and polyethylene (tibia) implants, and the left knee
served as a non-operated control. An intra-articular ALM or saline bolus (0.1 ml) was administered at the end of
surgery, and animals monitored for 4 weeks. Fibrotic changes were assessed by macroscopic examination,
histopathology, and expression of key inflammatory and fibrotic markers in the joint capsule and infrapatellar fat
pad (IFP).
Results: Knee swelling was evident in both groups at 4 weeks. However, range of motion was 2-fold higher in the
ALM-treated knees, and differences in macroscopic pathology indicated improved healing, compared to the control
group. Histologically, ALM treatment also led to significantly decreased synovitis and fibrotic pathology in the joint
capsule and IFP compared to saline controls. RNA and protein expression profiles of pro-fibrotic mediators (α-SMA,
TGF-β1, FGF1, PDGFA) were also significantly lower in knees from ALM-treated animals. In addition, the expression
of inflammatory mediators was lower in plasma (IL-1β, IL-10) and joint tissue (NFκB, IL-1β, IL-12), 4 weeks after surgery.
Conclusion: We show that intra-articular administration of a single ALM bolus significantly decreased fibrotic pathology
and synovitis in an experimental model of knee implant surgery, by blunting inflammation and modulating essential
genes of fibrosis. ALM has the therapeutic potential for translation into humans undergoing knee replacement surgery.
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Background
Stiffness and arthrofibrosis are common fibrotic joint
complications following knee surgery [1, 2]. Acquired
idiopathic stiffness accounts for up to 58% of repeat in-
terventions following primary total knee arthroplasty
(TKA) [3], and arthrofibrosis is responsible for up to
28% of 90-day hospital readmissions and 10% of revision
surgeries within the first 5 years of surgery [1, 4]. Post-
TKA arthrofibrosis reflects a more severe fibrotic path-
ology and restriction in joint function, with ~25% of
these requiring additional surgery and manipulation to
remove the adhesions and scar tissue [1, 4].
The key drivers of postoperative joint stiffness and fi-
brosis are believed to be excessive inflammation, the
proliferation of metaplastic fibroblasts, increased extra-
cellular matrix (ECM) proteins, and fibrous scar tissue
that leads to restricted joint motion and pain [1, 2, 5].
These secondary complications arise primarily from the
trauma of surgery and involve the synovial membrane,
extracapsular structures (e.g. medial and lateral liga-
ments) and the infrapatellar fat pad (IFP) [1, 2, 4–7].
Despite aggressive physical therapy regimens combined
with anti-inflammatory medications, there are no effect-
ive drugs that prevent stiffness or arthrofibrosis follow-
ing knee surgery. Previously, we have shown that
intravenous administration of adenosine, lidocaine and
Mg2+ (ALM) therapy reduces inflammation and second-
ary injury progression following hemorrhagic shock,
traumatic brain injury, and major surgery in rat and por-
cine models [8–14]. ALM has also been shown to im-
prove cell viability of human chondrocytes compared to
saline alone [15]. Based on ALM’s anti-inflammatory,
anti-ischemic, and coagulopathy correction properties,
we hypothesized that an intra-articular bolus adminis-
tered before skin closure may reduce arthrofibrosis in a
rat model of knee implant surgery.
Methods
Study design and surgical procedure
Conventional, twenty-week-old male Sprague-Dawley
rats (350 to 450 g) were used. Animals were individually
housed in ventilated cages (Tecniplast® Australia, NSW,
Australia) in a 14-10 h light-dark cycle under controlled
temperature (21-22 °C) and humidity (65–75%) condi-
tions, with access to standard rodent pellets (Specialty
Feeds, WA, Australia) and water ad libitum. Using a
random number generator (Research Randomizer.org)
animals were randomly allocated to treatment groups,
and within each treatment group, whether end-point tis-
sue samples were to be fixed (for microCT and hist-
ology, n = 6 per group) or snap-frozen in liquid nitrogen
(gene and protein expression, n = 6 per group). After a
7-day acclimation period, knee implant surgery was per-
formed on rats (n = 24) under isoflurane anesthesia using
surgical techniques and materials described previously
[16]. Surgeries were performed on 8 animals per surgery
day, with equal numbers of animals per treatment group
and randomization of the order of animals undergoing
surgery.
Three trained orthopedic surgeons contributed to this
study, with surgeons blinded to treatment groups and
surgeries conducted according to a standard protocol.
Surgeon contribution was equivalent across control and
treatment groups, with surgery time and blood loss com-
parable for both groups (Table S1). Briefly, a UHXLPE
implant was seated in a small mantle of gentamicin-
laden bone cement (Heraeus Palacos® R + G, Zimmer
Biomet, Sydney, Australia) within the proximal tibia. A
sterile titanium implant was press-fit into a defect cre-
ated in the distal femur. Following implantation, mild
abrasion of the synovium (medial and lateral gutters,
suprapatellar pouch, and retro patellar fat pad) was per-
formed using sterile dressing forceps, with a standard-
ized protocol of two passes each across each femoral
condyle and the medial and lateral tibial plateaus. Fol-
lowing patella repositioning, the capsule and skin were
closed with PDS II 5–0 (Ethicon, New Jersey, United
States of America) and monocryl 5–0 (Ethicon), respect-
ively. A continuous subcuticular technique was used for
skin closure and the surgical site swabbed with
povidone-iodine solution, then sprayed with OpSite™.
Immediately after skin closure and prior to recovery
from anesthesia, animals received pre-emptive analgesic
consisting of a 0.05 mg/kg subcutaneous injection of
buprenorphine (Temgesic®) in a 1 mL bolus of saline.
Postoperative analgesia (buprenorphine, 0.01–0.05 mg/
kg) was administered at 6 and 12 h post-surgery, with
analgesic administered 12-hourly thereafter, according to
pain scores of individual animals. Clinical signs including
body weight, temperature and weight-bearing activity
were monitored daily throughout the experimental
period. Animals were sacrificed 4 weeks post-surgery
with an overdose of pentobarbital (100 mg/kg) for gross
pathology, molecular and histological evaluation.
Treatment
Adenosine (A9251), Lidocaine-HCl (L5647), and MgSO4
(M7506) were purchased from Sigma-Aldrich. Animals
received an intra-articular (IA) bolus of ALM (0.1 ml; 1
mM adenosine, 3 mM lidocaine, and 2.5 mM MgSO4 in
0.9% NaCl) immediately following capsule closure and
prior to skin closure [8]. Control animals received an IA
bolus of 0.9% NaCl (0.1 ml) prior to skin closure.
Hematology, ROTEM and inflammatory assessments
Blood was collected under anesthesia via the lateral tail
vein during the experimental period or via terminal car-
diac puncture at 4 weeks post-surgery (Fig. S1).
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Complete blood cell examination was carried out using a
VetScan HM5 hematology analyzer (Abaxis, CA, USA).
Rotational thromboelastometry (ROTEM; Tem Inter-
national, Munich, Germany) was conducted on whole
blood according to manufacturer’s instructions. Three
60-min assays were performed simultaneously for each
sample: EXTEM (extrinsically activated test using tissue
factor), INTEM (intrinsically activated test using ellagic
acid), and FIBTEM (EXTEM-activated test with cytocha-
lasin D to inhibit platelet contribution to clot formation).
Parameters include clotting time (CT; seconds); alpha
angle (α°); clot amplitude (mm); maximum clot firmness
(MCF, mm); and maximum lysis (%).
Blood samples were centrifuged and plasma collected
and stored at -80 °C until further analysis. Vascular in-
jury markers (adiponectin, sE-selectin, sICAM-1, von
Willebrand Factor) were measured in plasma using
Milliplex® Rat Vascular Injury Magnetic Bead Panel 2
(Abacus ALS, Meadowbrook, Queensland), in combin-
ation with the Magpix® analyzer (Luminex Corporation,
Austin, Texas, USA). Inflammatory chemokines and cy-
tokines (MCP-1, TNF-α, IL-1β, IL-6, IL-12p70, IFN-γ,
IL-4, IL-10, TGF-β1) were measured in plasma and joint
tissue homogenates using Milliplex® Rat Cytokine/Che-
mokine Magnetic Bead Panel (Abacus ALS), and Rat
Transforming Growth Factor-β1 (TGF-β1) ELISA (Cusa-
Bio). Assays were performed according to manufacturer
instructions, with samples measured in duplicate. In-
flammatory markers in joint capsular tissue samples
were normalized to total protein (Pierce BCA protein
assay, ThermoFisher Scientific). Detection ranges for
analytes were 29.3–120,000 pg/ml for MCP-1, 15.3–60,
000 pg/ml for IFN-γ, 2.4–10,000 pg/ml for IL-1β and
TNF-α, 73.2–300,000 pg/ml for IL-6, 12.2–50,000 pg/ml
for IL-12p70, 4.9–20,000 pg/ml for IL-4, 7.3–30,000 pg/
ml for IL-10, 6.25–400 pg/ml for TGF-β, 0.1–40 ng/ml
for sICAM-1, 0.1–50 ng/ml for sE-selectin, 0.3–250 ng/
ml for adiponectin, and 0.7–500 ng/ml for vWF.
Joint angle measurement
The extension angle between the longitudinal axis of the
femur and the tibia was measured in triplicate using an
angulometer with 20 g force for both the right (operated)
and left (non-operated, control) knee [17]. Data are
expressed as the mean extension angle for control and
operated knees from saline- and ALM-treated animals.
Tissue harvest
Following blood collection at 4 weeks post-surgery, ani-
mals within each treatment arm were sacrificed to assess
joint tissue metrics. Macroscopic morphological analysis
of the intact joint, the articular surfaces, capsular and
synovial tissue was performed using a modified grading
system (Table S2) [18], with scores ranging from 0
(healthy, non-operated knee) to 9 (severe knee path-
ology). Knees were graded independently by two blinded
scorers and scores averaged. Agreement between scorers
was excellent, with an intraclass correlation coefficient
of 0.7 (95% CI 0.40 to 0.86), and the mean difference in
the score being 0.02 (95% CI, − 0.13 to 0.17).
Following evaluation of joint range of motion and
gross pathology, animals were perfused with ice-cold 0.1
M phosphate-buffered saline (PBS, pH 7.4). The oper-
ated (right) and non-operated control (left) knee were
dissected through a medial parapatellar approach using a
surgical blade (size 22). Anteromedial capsular tissue
(Fig. 1c) was separated from superficial tendons under a
dissection microscope, snap-frozen and stored at -80 °C
for subsequent RNA/protein extraction and analysis.
After removal of the patella and anteromedial capsule,
knees were fixed in 4% paraformaldehyde (PFA) for rou-
tine histology.
RNA isolation, cDNA synthesis, and real-time polymerase
chain reaction
Quantitative real-time reverse transcription polymerase
chain reaction (qPCR) was used to assess relative expres-
sion of selected genes involved in inflammation and fi-
brosis within joint capsule tissue. Briefly, snap-frozen
tissue (20 mg) was homogenised in 1 ml Trizol (Qiagen)
using disposable mortar and pestle. Total RNA was iso-
lated from dissociated tissue samples using the RNeasy
mini kit (Qiagen) according to manufacturer’s instruc-
tions. Primers were designed using the AlleleID software
(PREMIER Biosoft), and manufactured and purchased
from Merk (Table S3). The selection includes alpha-
smooth muscle actin-2 (Acta2), collagens (Col1a1,
Col3a1), matricellular proteins (Ccn2), growth factors
(Tgfb1, Fgf1, Pdgfa), metalloproteinases (Mmp3,
Mmp13), xylosyltransferase (Xylt1) and inflammatory
mediators (Nos2, Il1b, Il6). The relative expression of
each gene was calculated using the concentration-Ct-
standard curve method and normalized using the aver-
age expression of the housekeeping ribosomal protein
S13 (Rps13) gene for each sample using the Rotor-Gene
Q operating software version 2.0.24 (Qiagen). Rps13 was
chosen as the “housekeeping” gene since previous work
has shown its expression to be similar across rat tissue
types [14]. A one-step QuantiTect SYBR Green RT-PCR
Kit (Qiagen) was used in combination with the Quanti-
Tect Primer Assays (Qiagen) according to manufac-
turer’s instructions, with 20 ng of total RNA as template.
Histomorphometry
For routine histology, fixed intact knee joints were decal-
cified (14% EDTA), processed and paraffin-embedded.
Consistent with OARSI recommendations, sections
(4 μm) were cut in the frontal plane, spaced at 50 μm
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intervals and spanning the entire knee joint [19]. Stained
sections were visualized with light microscopy (Nikon
Eclipse i50; Japan) and digitized for histomorphometric
analysis using ImageJ® software (v1.52p; National Insti-
tutes of Health, EUA).
Medial capsule thickness was measured in hematoxylin
and eosin (H&E) stained sections (40x magnification),
with the mean capsule thickness of each animal deter-
mined from two sections and five individual measure-
ments per section. Semi-quantitative evaluation of
synovitis and fibrotic changes in the IFP was performed
by a blinded investigator on H&E-stained sections (40x
magnification) and according to the scoring system
adapted from Takahashi et al. [20] and Kitagawa et al.
[21] (Table S4). Masson-Goldner trichrome staining was
used to assess collagen density in the IFP. The mean
percentage of the green-stained area (indicating collagen
fibres) of trichrome-stained sections in comparison to
the total area was calculated using the Trainable Weka
Segmentation plugin in ImageJ.
For immunohistochemical analysis of α-SMA expres-
sion in capsular tissue and IFP, heat-mediated antigen re-
trieval was performed in citrate buffer (pH 6; Sigma
Aldrich, North Ryde, Australia) for 20min at 95 °C.
Endogenous peroxidase and phosphatase were blocked
with BLOXALL blocking solution (Vector Laboratories,
Burlingame, USA), and non-specific binding with
Animal-Free Blocker (Vector Labs). Sections were incu-
bated overnight at 4 °C with mouse anti-alpha smooth
muscle actin (α-SMA) antibody at 1:1000 dilution (1A4;
Abcam). A biotinylated secondary antibody (horse anti-
mouse/rat IgG; Vector Labs) was applied for 30min at
room temperature, followed by detection with an avidin-
biotin-based peroxidase kit (ABC Elite; Vector Labs). Im-
munoreactivity was visualized with 3,3′-diaminobenzidine
staining and sections counterstained with hematoxylin.
Semi-quantitative assessment of positive staining for α-
SMA was carried out by a blinded investigator on five
randomly selected high-powered fields (400x magnifica-
tion) per sections and two sections per joint.
Fig. 1 Macroscopic changes in knees at 4 weeks postoperative for animals that received an intra-articular bolus of ALM or saline immediately
following knee implant surgery, and prior to skin closure. a Compared to non-operated control knees, the circumference of implanted knees was
increased significantly for saline- and ALM-treated animals. b At 4 weeks post-surgery, the difference in the range of motion (ROM) in extension
for operated and non-operated knees tended to be greater for saline- compared to ALM-treated animals, though this difference was not
statistically significant. c Representative images of a non-operated knee, and knees from saline-treated and ALM-treated animals at 4 weeks post-
surgery. External views of the knee joints after removal of the skin (upper panel). Internal views of the joints following dissection (middle, lower
panels). Arrow indicates the location of the patella. Synovial thickening (asterisk), adhesions (white arrowhead) and articular cartilage roughness
(black arrowheads) were evident in operated knees. The yellow dotted line indicates the anteromedial region of capsular tissue dissected for
subsequent molecular analyses. d Adhesion of the synovium and femoral condyles was evident histologically (arrowheads, upper panels).
Macroscopic changes to articular surfaces corresponded to granulation tissue, fibrocartilage and subchondral bone remodeling (white arrows)
apparent on the femur (lower left panel) and tibia (lower right panel). e Macroscopic pathology scores were significantly reduced for the
operated joints that were administered intra-articular ALM, compared to saline controls. Data shows mean ± SD. *P < 0.05, vs. baseline (no surgery,
no treatment), #P < 0.05, compared to saline controls; n = 12 per group (circumference, ROM), n = 6 per group (macroscopic scoring)
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Statistics
Sample sizes (n) were determined from a priori power
analysis using G-power3 program (Heinrich-Heine-Uni-
versität Düsseldorf) using Acta2 gene expression as the
outcome measure with effect size Cohen’s d = 1.65 (Crit-
ical t = 1.96; df = 11; sample size = 6; α = 0.05; calculated
power = 0.84). Statistical analyses were performed using
GraphPad Prism for Mac software (version 7). Data nor-
mality was assessed using the Shapiro-Wilks test, with
Levene’s test used to determine equality of variances. In-
dependent samples t-tests were used for between-groups
comparison for normally distributed data (hematology
parameters, inflammatory cytokine concentrations).
Non-normally distributed data (joint angle, macroscopic
and histological scores, percentage positive α-SMA
staining) were compared using a Mann-Whitney U test.
MILLIPLEX Analyst 5.1 software (Luminex Corporation,
Austin, Texas, USA) was used to determine cytokine
and chemokine concentrations with a 5-parametric lo-
gistic weighted curve fit. Results are expressed as mean ±
standard deviation (SD), with significance set at P < 0.05.
Results
Operative and postoperative metrics
The time duration for knee implant surgeries, total time
under anesthesia and blood loss was comparable for
animals in saline- and ALM-treated groups (Table S1).
All animals recovered from anesthesia and were con-
scious and ambulant within 15 min. No animals showed
signs of infection, nor were there any deaths during the
experimental period. Minor weight loss occurred in the
first week post-surgery; however, all animals had
returned to pre-surgical body weights by 4 weeks post-
surgery (Table S5).
Gross inspection of macroscopic changes in the joint
Four weeks after surgery, animals were euthanized and
gross inspection of macroscopic changes in operated
knees was performed following removal of skin. Com-
pared to non-operated control knees, operated knees
were visibly enlarged at 4 weeks post-surgery, with knee
joint circumference increased 1.1-fold (P < 0.001; Fig.
1a). However, the joint circumference was comparable
for operated knees that were administered saline or
ALM intraoperatively (P = 0.396; Fig. 1a). Similarly, the
extension ROM of operated knees was lower than that
of native knees. Compared to non-operated knees, a
mean decrease of 4.2 and 2.2 degrees, respectively was
observed in extension ROM for saline-treated and ALM-
treated knees 4 weeks following surgery (P = 0.37; Fig.
1b). Upon joint dissection it was evident that increases
in the joint size of operated knees was associated with
expansion of the synovium and joint capsule, with adhe-
sions apparent in the operated knees (Fig. 1c). Mild-to-
moderate pathological changes were also evident on the
articular surfaces of the distal femur and proximal tibia
in operated knees, compared to non-operated control
knees (Fig. 1c). Histologically, these changes were associ-
ated with granulation tissue and eburnation of subchon-
dral bone (Fig. 1d). Macroscopic pathology scores were
1.5-fold lower for ALM-treated knees (2.8 ± 0.4) com-
pared to that administered saline (4.3 ± 1.4) at 4 weeks
post-surgery (P = 0.018; Fig. 1e).
Fibrotic changes in the infrapatellar fat pad
In contrast to the normal synovial membrane and uni-
form distribution of adipocytes observed in IFP from
non-operated knees, synovial hyperplasia (P = 0.0003;
Fig. 2a, b) and fibrous metaplasia (P = 0.002; Fig. 2a, c)
was evident in IFP from operated, saline-treated animals.
However, IFP from operated knees of ALM-treated ani-
mals exhibited less extensive histopathological changes
to subsynovial tissue (P = 0.033; Fig. 2a, c) than saline-
treated animals, and a trend for reduced synovitis (ns,
P = 0.123; Fig. 2a, c). Consistent with these findings, im-
munohistochemical analysis of the myofibroblast
marker, α-SMA demonstrated a 4.6-fold reduction in
staining in IFP from ALM-treated animals, compared to
those that received saline (P = 0.041; Fig. 2a, d). While
smooth muscles cells of blood vessels exhibited a strong
positive reaction, positive α-SMA staining was also evi-
dent in non-vascular cells (Fig. 2a). Similarly, a 1.4-fold
reduction in collagen deposition was observed in the IFP
of animals in the ALM-treatment group, compared to
those that received saline (P = 0.016; Fig. 2a, e).
Fibrotic changes, ECM remodeling and inflammation in
the joint capsule
A significant increase in medial joint capsule thickness of
operated knees in both saline and ALM-treated animals
was observed 4 weeks after surgery (P < 0.001; Fig. 3a, b).
However, compared to animals in the saline group, mean
medial joint capsule thickness in ALM-treated animals
was significantly reduced (1.4-fold; P = 0.015). An increase
in blood vessel density accompanied joint tissue hyperpla-
sia in in knees of saline controls. These histopathological
changes were ameliorated in animals that received intraar-
ticular ALM at the time of surgery (1.5-fold decrease, P =
0.02; Fig. 3a, c, d). Compared to saline-treated animals,
protein and gene expression of critical fibrotic markers, α-
SMA (3.1-fold decrease, P = 0.006 and 2.2-fold; P = 0.021
respectively; Fig. 3a, d, e) and TGF-β1 (1.8-fold decrease,
P = 0.467 and 3.2-fold decrease, P = 0.041; Fig. 3a, f, g),
were significantly lower in anteromedial joint tissue from
ALM-treated animals.
In addition to increased myofibroblast presence, the ex-
pression of key markers of tissue remodeling (MMP-3 and
-13, matrix metalloproteinases; XYLT1, xylosyltransferase-
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1), growth factors (CCN2, connective tissue growth factor;
PDGF, platelet-derived growth factor; FGF1, fibroblast
growth factor-1), and inflammatory pathway mediators
(NFκB, nuclear factor kappa B; IL-6, interleukin-6) con-
tributing to fibrosis were also measured. Compared to
saline-treated animals, mRNA expression of Fgf1 was 2.7-
fold lower (P = 0.041; Fig. 4c) and Pdgfa 1.9-fold lower
(P = 0.031; Fig. 4d) in capsular tissue from operated knees
of ALM-treated animals. Though no significant differ-
ences were observed between ALM-treated and saline
control operated knees for Col1a1, Col3a1, Mmp3,
Mmp13, Xylt1, Ccn2 and Il6 expression, the trend for re-
duction in these markers was similar to that observed for
Fgf1 and Pdgfa (Fig. 4a, b; Fig. S2). Compared to saline-
treated knees, expression of Nfkb and Nos2 was 1.7-fold
(P = 0.034; Fig. 4e) and 1.8-fold lower (ns, P = 0.154; Fig.
4f), respectively in ALM-treated joint capsular tissue, 4
weeks after surgery. While the concentration of IL-1β was
significantly elevated in capsular tissue from saline-treated
knees compared to non-operated knees (P = 0.043), levels
were 2-fold lower in ALM-treated knees and comparable
to those in non-operated knees (ns, P = 0.475; Fig. 4g).
Compared to non-operated knees, RANTES was elevated
in the joint tissue of operated knees 4 weeks after surgery,
and comparable between treatment groups (P < 0.001 and
P < 0.001, respectively; Fig. S2). Concentrations of IL-
12p70 (2-fold decrease; P = 0.077) and IL-2 (4.6-fold de-
crease; P = 0.051) also tended to be lower in joint capsule
from ALM-treated animals than those that received saline,
though differences were not statistically significant (Fig.
4h; Fig. S2). The additional cytokines investigated (IL-1α,
IFN-γ, IL-13, IL-10 and IL-6) remained below the assay
limit of detection in joint capsular tissue of non-operated
and operated knees, 4 weeks after surgery.
Systemic hematology and inflammation
Compared to pre-surgical levels, erythrocyte number
and hemoglobin were significantly reduced at day 3
post-surgery, returning to baseline levels by day 5 and
consistent with a normal physiological response to sur-
gery (Table S5). Leukocyte numbers remained compar-
able to baseline throughout the experimental period,
with no significant differences observed between saline-
and ALM-treated animals (Table S5). Both the number
and percentage of circulating granulocytes increased
transiently within the first 24 h of surgery in all animals.
However, compared to saline controls, the number of
granulocytes was significantly higher in the ALM-treated
Fig. 2 ALM reduced fibrosis in the infrapatellar fat pad following knee implant surgery. At 4 weeks post-surgery, intact knee joints from non-
operated, and operated knees of animals that received an intraoperative, intra-articular bolus of saline or ALM were decalcified and processed for
histology. a Representative stained section of the infrapatellar fat pad (IFP) (upper panels: hematoxylin and eosin; magnification, × 100; middle
panels: Masson Goldner trichrome magnification, × 100 and × 400; lower panels: α-SMA, magnification, × 400) from non-operated, operated
saline-treated and ALM-treated knees. Histopathological features of IFP inflammation were scored according to changes in the synovial lining
(arrowheads) and deposition of fibrotic tissue (f). Compared to saline controls, b synovitis, and c fibrosis was significantly reduced in IFP from
ALM-treated animals. Similarly, the percentage of tissue positive for d α-SMA and e collagen staining was significantly reduced in ALM-treated
knees, compared to saline controls. Data shows mean ± SD, *P < 0.05, vs. baseline (no surgery, no treatment), #P < 0.05, compared to saline
controls; n = 6 per group
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animals at 4 h (P = 0.026) and day 3 (P = 0.04) post-
surgery (Table 1; Table S5). Similarly, the number and
percentage of monocytes tended to increase transiently
postoperatively, with the percentage of monocytes sig-
nificantly higher for ALM-treated animals (P = 0.033)
than saline controls at day 5 (Table 1; Table S5). Conse-
quently, while the granulocyte:monocyte ratio remained
similar to preoperative levels in saline-treated controls,
the ratio decreased from day 1 in ALM-treated animals
and remained significantly lower than controls at day
5 following surgery (2-fold; P = 0.028; Table 1). Fur-
ther, due to the sustained increase in circulating
monocytes in ALM-treated animals, the monocyte:
lymphocyte ratio remained significantly elevated at
day 5 post-surgery compared to baseline and saline
controls (Table 1). Platelets remained comparable to
baseline levels in ALM-treated animals following
surgery. In contrast, the number of platelets increased
rapidly in saline controls and were significantly higher
than for ALM-treated animals at day 5 post-surgery
(2.4-fold; P = 0.005; Table S5).
Surgery-induced coagulopathy was evident in both
treatment groups indicated by significantly reduced clot
amplitudes (A10, MCF) and clot kinetics (α angle) on
EXTEM and INTEM tests at 4 h and day 1, with return
to baseline levels by day 3 post-surgery (Table S6). Max-
imum lysis was below 15% indicating no hyperfibrinoly-
sis in response to surgery in either group.
Plasma levels of IFN-γ and IL-6 increased significantly
from baseline at 4 and 24 h postoperative, returning to pre-
surgical levels within 5 days (Table 1; Table S5). A signifi-
cant increase was also observed for circulating IL-10 levels
at 4 h and 24 h post-surgery in saline controls and ALM-
treated animals, compared to baseline. However, plasma
Fig. 3 ALM reduces fibrosis in joint capsular tissue following knee implant surgery. Four weeks after knee implant surgery, animals were sacrificed
and anteromedial capsular tissue dissected from operated and non-operated knees. Remaining intact knee joints were decalcified and processed
for histology. a Representative stained section of the medial joint capsule (upper panels: hematoxylin and eosin; magnification, × 40; middle and
lower panels: α-SMA, magnification, × 100 and × 400) from non-operated, operated saline-treated and ALM-treated knees. b Thickness of the
medial joint capsule (black bar) was measured. At 4 weeks post-surgery, medial capsule thickness was significantly reduced in operated knees of
ALM-treated animals, compared to saline controls. c Compared to saline controls, blood vessel density was significantly lower in medial joint
capsular tissue from ALM-treated animals. d α-SMA staining was also significantly reduced in ALM-treated animals compared to controls. e
Similarly, mRNA expression of α-SMA (Acta2) was significantly reduced in joint capsular tissue from ALM-treated animals, compared to controls. f
Protein and g gene expression of TGF-β1 was also lower in the joint capsule of knees from ALM-treated animals. Data are expressed as mean ±
SD. Data shows mean ± SD, *P < 0.05, vs. baseline (no surgery, no treatment), #P < 0.05, compared to saline controls; n = 6 per group
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Fig. 4 Expression of key markers of ECM remodeling and inflammation in joint capsular tissue of ALM-treated and saline control animals, 4 weeks
following knee implant surgery. mRNA expression of a Col3a1:Col1a1 ratio, and b Xylt1 tended to be lower in capsular tissue from ALM-treated
animals, compared to controls, though these differences were not statistically significant. Compared to controls, c Fgf1, and d Pdgfa expression
was significantly lower in joint tissue from ALM-treated animals. Compared to controls, mRNA expression of e NFkB1 and f NOS2 and protein
expression of g IL-1β, and h IL-12p70 was lower in the ALM treatment group. Data are expressed as mean ± SD. *P < 0.05, vs. baseline (no
surgery, no treatment), #P < 0.05, compared to saline controls; n = 6 per group
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IL-10 levels remained significantly higher in animals that
received saline alone at day 5, and 4 weeks post-surgery,
compared to those administered ALM (P = 0.008 and P =
0.005, respectively; Table 1). Similarly, levels of the proin-
flammatory cytokine IL-1β were significantly elevated in
plasma from saline controls compared to animals adminis-
tered ALM at 4 weeks post-surgery (P = 0.025; Table 1). No
significant changes were observed in plasma concentrations
of MCP-1, TNF-α, IL-12p70, or IL-4 following surgery,
with levels comparable for saline controls and ALM-treated
animals at all timepoints investigated (Table S5).
Endothelial activation
To compare the extent of vascular injury in ALM- and
saline-treated animals, four soluble cellular adhesion
molecules (sICAM, sE-selectin, adiponectin and vWF)
Table 1 Hematology and systemic inflammatory responses
Indices Baseline Time Saline Control ALM
Granulocytes
x 109cells/L
3.0 ± 2.0 4 h 5.4 ± 1.9 8.6 ± 2.1*^
day 1 6.4 ± 2.8 8.3 ± 1.2*
day 3 2.8 ± 1.5 4.9 ± 1.6^
day 5 2.7 ± 1.6 3.3 ± 1.2
day 28 2.1 ± 1.3 2.7 ± 1.4
Monocytes
x 109cells/L
0.5 ± 0.7 4 h 0.3 ± 0.2 0.6 ± 0.7
day 1 0.8 ± 0.4 0.8 ± 0.3
day 3 0.4 ± 0.7 1.1 ± 1.0
day 5 0.4 ± 0.8 1.1 ± 0.8
day 28 0.4 ± 0.5 0.6 ± 0.6
Granulocyte:Monocyte ratio 23.4 ± 17.7 4 h 41.2 ± 35.6 37.1 ± 35.6
day 1 13.8 ± 13.0 12.2 ± 8.4
day 3 30.2 ± 22.7 15.8 ± 22.6
day 5 21.2 ± 15.8 10.4 ± 16.3*^
day 28 22.3 ± 20.9 16.1 ± 17.5
Monocyte:Lymphocyte ratio 0.06 ± 0.09 4 h 0.12 ± 0.12 0.18 ± 0.21
day 1 0.22 ± 0.1* 0.17 ± 0.07
day 3 0.06 ± 0.08 0.14 ± 0.12
day 5 0.06 ± 0.08 0.12 ± 0.07*^
day 28 0.08 ± 0.09 0.08 ± 0.07
IL-1β, pg/ml 5.7 ± 3.8 4 h 8.6 ± 7.1 9.7 ± 12.9
day 1 6.1 ± 2.5 10.6 ± 8.8
day 3 3.9 ± 2.2 5.7 ± 2.3
day 5 2.9 ± 2.4 5.0 ± 5.3
day 28 17.0 ± 12.9* 7.4 ± 4.2^
IFN-γ, pg/ml n.d.a 4 h 52.5 ± 24.6* 32.7 ± 21.3*
day 1 43.2 ± 31.6* n.d.
day 3 33.1 ± 24.4 n.d.
day 5 24.7 ± 5.6 23.6 ± 2.0
day 28 n.d. n.d.
IL-10, pg/ml 16.3 ± 10.3 4 h 60.4 ± 30.0* 67.1 ± 54.9*
day 1 37.4 ± 12.4* 46.4 ± 30.9*
day 3 40.1 ± 15.7* 42.7 ± 12.8*
day 5 32.0 ± 9.9* 21.7 ± 15.0^
day 28 53.7 ± 33.9* 25.0 ± 14.2^
4 h, day 1 and 3, n = 6; day 5 and 28, n = 12. Baseline values were obtained from tail vein of 8 healthy anesthetised rats (refer Methods). Data represent mean ± SD
n.d. not detected
*P < 0.05 compared to baseline. ^P < 0.05 compared to saline. a limit of detection IFN-γ, 15.3 pg/ml
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were measured in plasma at 4 h and day 1 post-
surgery (Table S5). sICAM levels remained compar-
able to preoperative ranges. In contrast, concentra-
tions of sE-selectin, adiponectin and vWF increased
significantly from baseline within 4 h of surgery. How-
ever, no differences were observed in concentrations
of these vascular injury markers between saline and
ALM-treated animals at either time point (Table S5).
Discussion
Acquired idiopathic stiffness and arthrofibrosis following
primary TKA are common causes of reduced ROM and
postoperative pain, often requiring extended rehabilita-
tion programs and/or repeat surgical correction [3]. In
this study, we report that IA administration of ALM at
the end of knee implant surgery in the rat appears to in-
crease ROM and to improve healing after 4 weeks, with
the macroscopic restoration of healthy joint tissue archi-
tecture. We also showed that ALM significantly de-
creased fibrotic markers within synovial and capsular
tissue of the implanted knee, compared to controls.
These fibrotic changes paralleled a reduction in systemic
inflammation immediately following, and joint tissue in-
flammation over the four-week postoperative period.
ALM therapy reduces fibrotic changes in the infrapatellar
fat pad
The finding that ALM significantly reduced the expres-
sion of α-SMA, a marker for myofibroblasts which are
the critical cell mediators of fibrosis [22], suggests that
the drug therapy may have reduced fibrosis in the IFP in
our TKA model. The histological assessment of the IFP
further supports this (Fig. 2). Although the IFP is com-
monly removed by surgeons to assist with the alignment
and fitting of the artificial knee components and reduce
postoperative anterior knee pain [23], others argue that
its’ removal is unnecessary [24]. Given that the IFP is
highly vascularized at the periphery and richly inner-
vated with nerves and lymphatic vessels, it plays a sig-
nificant role in local and systemic immune responses to
surgery. For example, the IFP contains adipocytes, prea-
dipocytes, macrophages, fibroblasts, and other cells that
secrete cytokines, adipokines, and other neural, inflam-
matory and metabolic mediators [25] that may have pro-
tective functions beyond the joint [26]. Given that there
is little experimental support that removal of the IFP re-
duces postoperative pain [24], ALM-induced reduction
of inflammation and fibrosis may have wider significance
for IFP preservation during TKA and may confer im-
mune benefits for the patient [27]. Protecting the IFP
with ALM may also have utility in minimally invasive
arthroscopic procedures such as meniscectomy and ACL
reconstruction.
ALM therapy reduces fibrosis, ECM remodeling and
inflammation in the joint capsule
Our study also showed that ALM protection extended to
the joint capsule itself. ALM protection manifested as
significant decreases in expression of TGF-β, FGF1,
PDGFA and α-SMA in joint tissue, and tendency for
lower expression of XT-1 and CCN2, compared to saline
controls (Figs. 3, 4). Histologically, joint tissue from
ALM-treated animals exhibited significant reductions in
synovitis, myofibroblasts, proteoglycan accumulation
and blood vessel density, and more closely resembled
healthy joint capsule architecture than controls. Sup-
pression of inflammation in ALM-treated knees, was
also supported by decreased levels of key immune medi-
ators IL-1β, IL-12 and iNOS (nitric oxide production) in
capsular tissue (Fig. 4). Of particular importance to cre-
ating a more permissive healing environment, ALM
markedly reduced expression of NFκB, a prime driver of
inflammation and fibrosis [2], compared to controls.
Currently, we do not know if ALM directly inhibits the
NFκB signaling pathway, or exerts indirect effects via
upstream mediators.
ALM alters early postoperative systemic inflammatory
responses
Granulocyte and monocytes are key effector cells of the
innate immune response. The transient increase in gran-
ulocytes and monocytes observed in all animals at 4 h
and day 1 postoperative (Table 1) is consistent with the
systemic inflammatory response to anesthesia and surgi-
cal trauma [8, 10, 12, 16, 28, 29]. Within minutes to
hours of tissue trauma, granulocytes (mostly neutro-
phils) are rapidly mobilized from the circulation and
bone marrow to local sites, followed later by monocytes
[28]. Together with tissue-resident cells, they are key or-
chestrators of the cellular and molecular events of the
acute inflammatory response required to mitigate further
tissue damage and facilitate healing. Following surgery,
we showed that circulating total leukocyte numbers were
comparable for both treatment groups (Table S5). How-
ever, in ALM-treated animals we found significant dif-
ferences in the proportion of granulocytes and
monocytes over the first 5 days compared to controls
(Table 1). In the first 3 days following surgery, there was
a spike in granulocytes in the ALM group followed by a
steady rise in monocytes to day 5. In contrast, circulating
monocyte numbers remained comparable to preopera-
tive levels in saline controls over the same period (Table
1, Table S5). This is also reflected in the significantly
lower granulocyte:monocyte ratio at day 5 in ALM ani-
mals (Table 1). This time-dependent progression of neu-
trophils and monocytes can profoundly impact the
duration and magnitude of subsequent inflammatory,
immune and tissue repair responses [28, 30].
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While we did not measure immune cells at the injury
site, the data indicate that ALM may act as an inflamma-
tory brake, in turn leading to reduced fibrosis and im-
proved joint tissue healing. This hypothesis is further
supported by control animals showing persistent inflam-
mation (Table 1, Fig. 4) systemically and within joint tis-
sues of the implanted knee at 4 weeks postoperative.
Also, surgery-induced IL-10 plasma concentrations,
which are associated with decreased long-term func-
tional performance in the operated limb following TKA
[31], were also lower in ALM-treated animals (Table 1).
Further investigations are warranted to elucidate the
molecular and cellular mechanisms underpinning the ef-
fect of ALM on inflammation resolution within the local
microenvironment of the operated knee in the early
postoperative period.
Limitations of the study
A potential limitation of the rat model used in the
present study is that it may not reflect some aspects of
the tissue trauma evoked following TKA [1]. Patients
undergoing TKA will already have pre-existing trauma
and inflammation from osteoarthritis and most have
multiple comorbidities, which may affect the duration of
the operation, and extent of inflammation and recovery
[1, 32]. The rat TKA model however, does elicit a strong
trauma-induced inflammatory response leading to joint
fibrosis, and is useful for studying biochemical and histo-
logical changes underpinning recovery dynamics [16].
Although we demonstrated an association between early
inflammatory responses and 4-week pathology, in future
studies it would be essential to investigate the changes
in joint tissue inflammation and immune cell infiltration
within the first week of knee implant surgery. Western
blot analysis could also be performed to support the
mRNA expression and histological data. Further studies
will also employ microCT to investigate the effect of
ALM on osseointegration of TKA prostheses. Overall,
while not reproducing the damaged knee of the TKA pa-
tient, the rat model of knee implant surgery is a useful
model to study the effect of new drugs and underlying
mechanisms controlling inflammation as part of their
translation to improve outcomes in humans.
Clinical relevance
TKA is one of the most commonly performed inpatient
surgical procedures globally, and it is estimated to
reach 3.48 million procedures in the USA annually by
2030 [32].
Arthrofibrosis is a common perioperative complication
with debilitating consequences [1, 2]. Our study shows
ALM administration into the joint after capsule closure,
and before skin closure has the potential to reduce
inflammation, stiffness and arthrofibrosis in the TKA
patient. To date, alternative immunomodulatory candi-
dates for arthrofibrosis require sustained or repeated
drug administration to reduce fibrotic tissue within the
knee [33, 34]. An advantage of ALM therapy is that a
single local injection into the joint is required for its
benefit. This benefit cannot be afforded by the individual
actives A, L or M alone; rather, it is the combination
that reduces inflammation, coagulopathy, and ischemia-
reperfusion injury [8, 10–14, 35, 36]. What is most inter-
esting, is that the circulating half-lives of A, L and M are
seconds to hours, yet in the present study we show the
benefit can last 4 weeks, indicating that ALM is acting
early to ‘switch’ to an improved healing phenotype [11,
14]. Future studies will elucidate the molecular pathways
underlying ALMs anti-inflammatory, pro-resolving, and
anti-fibrotic properties before translation into humans.
Conclusions
In conclusion, the present study demonstrates that IA
administration of a single ALM bolus before skin closure
alleviated post-TKA knee fibrosis in a rat model. ALM
therapy appears to modulate inflammatory mediators in
the early postoperative period, favoring tissue repair ra-
ther than fibrosis. Our findings provide support for fur-
ther evaluation of ALM therapy as an upfront strategy
for improved healing and recovery after TKA, and pos-
sibly other orthopedic procedures.
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